Stock Trading

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the BIOCOM Investor Conference on Monday, October 26, 2009, at 10:00 a.m. Pacific time, at the Hyatt Regency in La Jolla, California.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

NDA Submission for ANX-530 on Track


SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today provided an update on its business that included the intended use of proceeds from recent financings, the status of its product candidates ANX-530 and ANX-514, and its plan for the listing of its common stock. The Company also commented on the recent resignations of Alexander J. Denner and Mark N.K. Bagnall from its Board of Directors.
The Company's current outlook reflects its bolstered cash position following the closing of a financing earlier this month that provided approximately $6 million in proceeds (after deducting amounts placed in an escrow account to make dividend and other payments due with respect to the convertible preferred stock sold in the financing, but before deducing placement agent fees and offering expenses). The Company also raised approximately $3.8 million in proceeds in three separate offerings in June, July and August of 2009.

"This latest equity offering eliminated a substantial amount of financing risk," said Brian M. Culley, Principal Executive Officer at ADVENTRX. "We believe we now have the funds to support operations well into 2010 and, importantly, through the significant milestone of an FDA decision on ANX-530. Our ability to attract investment capital on four separate occasions in a difficult market is a positive testimonial for our cost-effective business model, our lower-risk product candidates and our core formulation technology."

ADVENTRX stated it plans to use the majority of the proceeds from its latest offering to fund its operations during the FDA review period of an ANX-530 NDA. The Company reiterated that it intends to submit the NDA for ANX-530 by the end of 2009. ADVENTRX also continues to evaluate its options for ANX-514, a reformulation of docetaxel. "We remain confident in the potential of this product candidate, and look forward to discussing the results of our clinical bioequivalence study of ANX-514 with the FDA," said Mr. Culley.

The Company also announced that is has indefinitely postponed a previously announced plan to voluntarily withdraw its common stock listing from the NYSE Amex and list on the NASDAQ Capital Market. The Company will remain on the NYSE Amex under the symbol "ANX."

Finally, ADVENTRX commented on the resignation of Alexander J. Denner from its Board of Directors, noting that the resignation was not the result of a disagreement with the Company on any matter relating to its operations, policies or practices.

"Dr. Denner's recent resignation, as well as Mark's in August, are consistent with our transformation to a leaner, specialty pharmaceutical company leveraging an innovative drug development strategy that seeks to bring improved versions of existing therapies to patients in a quick and efficient manner. Alex's views and advice, over the past year in particular, have been invaluable, and we wish him the best."

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

ANX +28% very nice finish once again congrats to all who got in on our alert at the opening bell.

ANX up nicely the past few days on this news from Dec 9

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences On-line Forum on December 15, 2009 at 9:30 a.m. Eastern time.

Interested parties can access a live audio webcast with slide presentation at www.informedinvestors.com, a link to which is available on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.